Form 8-K/A · Current Report · Filed 2024-05-03
Hologic Reports Second Quarter 2024 Results and Raises Guidance
Hologic, Inc. reported financial results for the second quarter of fiscal 2024, showing a slight decrease in GAAP and non-GAAP revenues but exceeding guidance on organic revenue growth and non-GAAP earnings per share. The company also raised its full-year revenue and earnings guidance. The press release corrected a reference to guidance for the second quarter to the third quarter, and provided detailed financial tables and non-GAAP reconciliations.
- Filer
- Hologic Inc. HOLX · NASDAQ
- Filed
- Accession
- 0001140361-24-024213
- CIK
- 0000859737
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$75.91
Next session
+0.0%
Since filing
+0.1%
Latest close
$76.01
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HOLX reporting the same item, with the next session's move:
Exhibits (1)
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Never miss another HOLX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.